MichaelBoyiadzisMD

Oncology • Pittsburgh, PA

Assistant Professor, Medicine, University of Pittsburgh School of Medicine

Join to view full profile

Are you Dr. Boyiadzis?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 47 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
200 Meyran Ave
Suite 318
Pittsburgh, PA 15213
Phone+1 412-586-9874

Fax+1 412-647-4486

Summary

Dr. Michael Boyiadzis, MD is an oncologist in Pittsburgh, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania and Maryland. He is affiliated with UPMC Presbyterian Shadyside, UPMC Magee-Womens Hospital, and Shadyside Campus.

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2001 - 2005
St Agnes HealthCareResidency, Internal Medicine, 1998 - 2001
University of Debrecen Medical and Health Science CenterClass of 1995

Certifications & Licensure

PA State Medical License 2004 - 2024
MD State Medical License 2001 - 2006

Clinical Trials

Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia Start of enrollment: 2008 Sep 01
Terminated
Phase 1
QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia Start of enrollment: 2014 May 12
Completed
Phase 1
Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia Start of enrollment: 2012 Dec 13
Completed
Phase 3
Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2013 Oct 01
Terminated
Phase 2
Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia Start of enrollment: 2017 Oct 17
Withdrawn
Early Phase 1
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy Start of enrollment: 2019 Feb 28
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia.
Kevin Quann, Konstantinos Lontos, Alison Sehgal, Anastasios Raptis, Annie Im
Haematologica. 2024-12-01
1 citations
Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.
Annie Im, Kevin Quann, Mounzer Agha, Anastasios Raptis, Robert L Redner
American Journal of Hematology. 2024-03-01
7 citations
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Sheng F Cai, Ying Huang, Jennie R Lance, Hsiaoyin Charlene Mao, Andrew J Dunbar
Blood Advances. 2024-01-23

Press Mentions

DPP4+ Exosomes in AML Patients’ Plasma Suppress Proliferation of Hematopoietic Progenitor CellsNovember 2nd, 2020